Cooley: Tenet Medicines to Be Acquired by Eliem Therapeutics
April 16, 2024
April 16, 2024
BOSTON, Massachusetts, April 16 -- Cooley, a law firm, issued the following news release:
Cooley advised Tenet Medicines, a development-stage private biotechnology company, on its definitive agreement to be acquired by Eliem Therapeutics (Nasdaq: ELYM), a biotech company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems.
. . .
Cooley advised Tenet Medicines, a development-stage private biotechnology company, on its definitive agreement to be acquired by Eliem Therapeutics (Nasdaq: ELYM), a biotech company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems.
. . .